Chemomab Therapeutics (CMMB) Other financing activities (2020 - 2023)

Chemomab Therapeutics' Other financing activities history runs 4 years deep, the most recent figure standing at -$14.2 million for Q4 2023.

• Quarterly Other financing activities fell 17365.85% year-over-year to -$14.2 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$10.0 million (down 7125.17% YoY) and the FY2025 annual result came in at $12000.0, changed N/A from the prior year.
• Other financing activities was -$14.2 million for Q4 2023 at Chemomab Therapeutics, down from $4.0 million in the prior quarter.
• Across five years, Other financing activities topped out at $4.0 million in Q3 2023 and bottomed at -$14.2 million in Q4 2023.
• A 4-year average of -$796727.3 and a median of $82000.0 in 2022 frame the typical range for Other financing activities.
• Peak annual rise in Other financing activities reached 10133.33% in 2023, while the deepest fall reached 17365.85% in 2023.
• Chemomab Therapeutics' Other financing activities stood at $563000.0 in 2020, then slumped by 98.22% to $10000.0 in 2021, then soared by 720.0% to $82000.0 in 2022, then tumbled by 17365.85% to -$14.2 million in 2023.
• Business Quant data shows CMMB's Other financing activities at -$14.2 million in Q4 2023, $4.0 million in Q3 2023, and $82000.0 in Q4 2022.